Role of extra cellular proteins in gastric cancer progression and metastasis: an update

Mohammad Reza Abbaszadegan1, Majid Mojarrad2 and Meysam Moghbeli2*

Abstract

Background: Gastric cancer (GC) is one of the most common cancers in the world with a high ratio of mortality. Regarding the late diagnosis, there is a high ratio of distant metastasis among GC cases. Despite the recent progresses in therapeutic modalities, there is not still an efficient therapeutic method to increase survival rate of metastatic GC cases.

Main body: Apart from the various intracellular signaling pathways which are involved in tumor cell migration and metastasis, the local microenvironment is also a critical regulator of tumor cell migration. Indeed, the intracellular signaling pathways also exert their final metastatic roles through regulation of extra cellular matrix (ECM). Therefore, it is required to assess the role of extra cellular components in biology of GC.

Conclusion: In the present review, we summarize 48 of the significant ECM components including 17 ECM modifying enzymes, seven extracellular angiogenic factors, 13 cell adhesion and cytoskeletal organizers, seven matricellular proteins and growth factors, and four proteoglycans and extra cellular glycoproteins. This review paves the way of determination of a specific extra cellular diagnostic and prognostic panel marker for the GC patients.

Keywords: Gastric Cancer, Extra cellular matrix, Metastasis, Microenvironment

Background

The local microenvironment has critical role in regulation of cell functions [1]. The extracellular matrix (ECM) as non-cellular component of microenvironment has important roles in tissue dynamic, morphology, and functions [2]. Therefore, ECM aberration can be associated with abnormal behaviors of cells and tissue homeostasis which results in various disorders such as fibrosis and cancer [3, 4]. The proteins, proteoglycans, polysaccharides, and minerals are some of the main components of ECM that shape basement membrane and interstitial matrix [5]. ECM is composed of various proteins such as collagens, laminins, proteoglycans, and remodeling enzymes. Beside the structural roles, the ECM is associated with signaling pathways and growth factors through binding with BMPs, FGFs, hedgehogs, and WNTs [2]. Therefore, aberrant ECM composition can be oncogenic. ECM degrading enzymes including metalloproteinase and serine protease have destructive influences on tissues which highlights the regulatory role of ECM remodeling enzymes during transcriptional, translational, and post-translational levels [6, 7]. Type I collagen is the most common type in interstitial matrices, whereas type IV collagen is essential in basement membrane [8]. Collagens function as a scaffold to facilitate tumor cell migration [9]. Increased collagens deposition have been reported during tumor formation [10]. Aging decrease and increase collagen deposition and MMP activity, respectively. Abnormal ECM dynamics promote epithelial mesenchymal transition (EMT) via basement membrane disruption using MMPs up regulation which is a critical
step during tumor progression [11, 12]. Since the EMT results in cancer stem cell-like properties and drug resistance, it facilitates tumor metastasis [13, 14]. Tumor angiogenesis is also another process associated with ECM in which many ECM components such as endostatin, arresten, and hexastatin have inducing or inhibitory angiogenic functions [15]. The G1/S cell cycle progression is also associated with ECM-cell adhesion in which the ECM activate growth factor through ERK signaling [16, 17]. Moreover, the immune cell processes such as infiltration and activation can be affected by ECM [18].

Carcinogens exert their impact through DNA damage, aberrant cellular processes, and microenvironment alterations [19]. The effects of majority of carcinogens are occurred through modulation of tumor microenvironment. Tumorigenesis is associated with activation of various cell types such as stem cells, fibroblasts, and hematopoietic cells which recruit immune cells to produce cytokines [20, 21]. Carcinogens can change the functions of these cells and ECM components [22]. Tissue remodeling is known by changes in expression and degradation of ECMs [23]. Matrix metalloproteinases (MMPs) as the main ECM remodelers can be affected by carcinogens. Chronic exposure to heavy metals, nicotine, and radiation are associated with tissue remodeling [24, 25]. Moreover, some chemicals regulate tissue remodeling through up regulation of growth factors, cytokines, and extracellular proteins in host cells. These alterations in tissue remodeling genes results in tissue architecture changes which promotes tumor progression [26].

Gastric Cancer (GC) is the fourth common and the second leading cause of cancer-related deaths in the world [27]. Distant metastases are observed among a noticeable ratio of GC patients at the time of diagnosis which have not an effective treatment (5-year survival rate is up to 10%) [28–30]. Therefore, introduction of circulating biomarkers can be helpful to improve early detection and prognosis in such patients. Increased protein-specific fragments belonged to the ECM turnover are released into blood following an aberrant ECM remodeling which can be used as circulating biomarkers for diagnostic and prognostic purposes in cancer patients [31]. Since the main reason of distant metastasis is local microenvironment and extracellular matrix, in the present review, we summarize 47 of the significant ECM proteins which have been reported until now among GC patients in the world including 17 ECM modifying enzymes, seven extracellular angiogenic factors, 12 cell adhesion and cytoskeletal organizers, seven matricellular proteins and growth factors, and four proteoglycans and extra cellular glycoproteins (Table 1). Official symbol, official full name, gene ID, and URL of the reported genes in the present study referred from National Center for Biotechnology Information (https://www.ncbi.nlm.nih.gov) are also presented in Table 2.

**Main text**

**ECM modifying enzymes**

In this section, we summarize 17 gene products including seven metalloproteinases (MMP1, MMP2, MMP7, MMP9, MMP14, MMP24 and MMP25), laminin subunit gamma 2 (LAMC2), three ADAMTS metallopeptidases (ADAMTS1, ADAMTS8 and ADAMTS18), 2 TIMP metallopeptidases (TIMP1, TIMP3), three lysyl oxidase (LOX, LOXL4, and PLOD2), and tissue factor pathway inhibitor 2 (TFPI2).

Matrix metalloproteinases (MMPs), heparanase, cathepsins, urokinase plasminogen activator, and lysyl oxidase are ECM modifying enzymes contributing with tumor metastasis [77–79]. Degradation of ECM is mainly mediated by MMPs which are zinc dependent endopeptidases secreted by various cells such as fibroblasts and endothelial cells. Their activation is depended to the calcium and neutral pH [80, 81]. MMPs are categorized based on their substrate and cellular location into four groups including collagenases, stromelysins, gelatinases, and membrane-associated MMPs. Regulation of ECM through MMPs has a key role in tumor progression and metastasis [82]. Beside other proteases, the MMPs can also activate variety of factors such as tyrosine-kinase receptors, growth factors, and cell-adhesion molecules [7, 80]. Type IV collagen is one of the main components of basal membranes and ECM which can be degraded via MMP2 and MMP9 [83]. The 1562C/T promoter polymorphism of MMP9 has been assessed in a sub population of Japanese GC cases which showed higher frequency of T allele in advanced-stage GC cases. Moreover, T allele significantly increased the lymph node involvement [32]. Another study has been reported that there were correlations between MMP9 expression, stage, depth of tumor invasion, and lymph node involvement which suggested the MMP9 as a marker of GC metastasis [33]. MMP9 had significant increased levels of expression in advanced stage tumors in comparison with early gastric tumors [34]. MMP1 as a collagenase has a critical role in ECM remodeling. It can be regulated by various transcription factors such as AP1, AP2, and retinoic acid [84]. The 1G/2G promoter polymorphism of MMP1 was assessed in GC patients and showed that there was a significant correlation between 2G allele and poorly differentiation [35]. It has been shown that there was a correlation between rs1799750 and GC in which the patients had significantly higher frequency of 2G allele compared with controls. Moreover, the 2G/2G carriers significantly had higher risk of tumor invasion in comparison with 1G/1G + 1G/2G genotype [36]. MMP2 has a key role in primary steps of tumor progression [85]. Cyclo-oxygenase 2 (COX2) is also associated with inflammation and tumorigenesis that up regulates the MMPs through prostanoids [86]. It has been reported that the epithelial MMP2 expression was correlated with COX2 over expression in GC
Table 1: All of the ECM related factors involved in gastric cancer progression and metastasis

| Gene name                      | Results                                                                 | Country | population   | Year  | Reference   |
|-------------------------------|-------------------------------------------------------------------------|---------|--------------|-------|-------------|
| **ECM modifying enzymes**     |                                                                         |         |              |       |             |
| MMP9                          | Polymorphism was correlated with invasive phenotype                      | Japan   | 177 patients | 2005  | Matsumura [32] |
| MMP9                          | MMP9 expression was correlated with stage, depth of tumor invasion, and lymph node involvement | Poland  | 54 patients  | 2009  | Mroczko [33] |
| MMP9                          | increased levels of expression in advanced stage tumors                 | Serbia  | 40 patients  | 2009  | Dragutinovic [34] |
| MMP1                          | Polymorphism was correlated with poorly differentiation                 | Japan   | 215 patients | 2004  | Matsumura [35] |
| MMP1                          | Polymorphism was correlated with GC risk                                 | China   | 422 patients | 2014  | Dedong [36] |
| MMP2                          | MMP2 expression was correlated with poor survival, stage, and diffuse type | Finland | 315 patients | 2006  | Mrena [37] |
| MMP14                         | High levels of serum MMP14 was correlated with poor survival            | Finland | 240 patients | 2018  | Kasurinen [38] |
| MMP7 and LAMC2                 | MMP7 and LAMC2 expressions were correlated with tumor aggressiveness     | Japan   | 790 patients | 2014  | Sentani [39] |
| ADAMTS3, ADAMTS18, and ADAMTS1 | Expressions were correlated with stage                                  | Turkey  | 25 patients  | 2017  | Kilic [40] |
| TIMP1                         | TIMP1 expression was correlated with advanced stages, increased depth of invasion, and metastatic lymph nodes | Poland  | 54 patients  | 2009  | Mroczko [41] |
| MMP2, MMP24, and MMP25        | MMP2, MMP24, and MMP25 increased expression                             | Mexico  | 17 patients  | 2014  | De la pena [42] |
| LOX                           | Over expression was correlated with local tumor relapse                  | China   | 184 patients | 2018  | Peng [43]   |
| LOXL4                         | Over expression was correlated with tumor size, depth of invasion, stage, and survival | China   | 379 patients | 2015  | Li [44]     |
| PLOD2                         | Expression was correlated with peritoneal metastasis                     | Japan   | 179 patients | 2018  | Kiyozumi [45] |
| TFPI2                         | Hyper methylation                                                       | China   | 114 patients | 2017  | Hu [46]     |
| ETS1                          | over expression induced mucosal into the sub mucosal tumor invasion     | Japan   | 110 patients | 1996  | Nakayama [47] |
| **Extra cellular angiogenic factors** |                                                                         |         |              |       |             |
| BSG                           | Expression was correlated with tumor size and lymph node metastasis     | Japan   | 234 tumors  | 2006  | Zheng [48] |
| MMRN2, EMILIN1, and EMILIN2    | High expression of MMRN2 in normal gastric mucosa along blood vessels, while the EMILIN2 and EMILIN1 expressions were limited to the lamina propria. | Italy   | 51 patients  | 2018  | Andreuzzi [49] |
| HPSE                          | Polymorphism was correlated with survival                               | China   | 155 patients | 2010  | Yue [50] |
| CTHRC1                        | Expression was correlated with depth of invasion                        | China   | 116 patients | 2012  | Wang [51] |
| CTHRC1                        | Expression was associated with tumor stage, differentiation, survival, and prognosis, depth of invasion, lymph node involvement, and tumor size. | China   | 166 tumors  | 2014  | Gu [52] |
| ECM1                          | Expression was correlated with tumor relapse, poor survival, and advanced stages. | China   | 241 patients | 2018  | Gan [53] |
| ECM1                          | Expression was correlated with tumor depth of invasion and stage.       | China   | 77 patients  | 2014  | Wu [54] |
| **Cell adhesion and cytoskeletal organizers** |                                                                         |         |              |       |             |
| PCDH8                         |                                                                         | China   | 144 patients | 2018  | Lin [55] |
| CLDN4                         | Expression was correlated with depth of invasion and lymph node involvement | Taiwan | 189 patients | 2010  | Hwang [56] |
| LLGL1                         | Was correlated with distant metastasis.                                 | Germany | 56 patients  | 2019  | Desuki [57] |
patients. Moreover, there were correlations between stromal MMP2 expression, poor survival, stage, and diffuse type, whereas the MMP9 was associated with intestinal type [37]. MMP14 is belonged to the membrane-bound MMPs. It has been observed that the serum MMP14 was an independent prognostic factor of GC in which the men with high levels of serum MMP14, pT3–4 tumors, and metastatic lymph nodes had poor survival [38]. MMP7 targets various ECM components such as collagens, elastin, and fibronectin. Laminins are associated with cellular adhesion and differentiation [87].

Laminin subunit gamma 2 (LAMC2) is expressed in tumor cells and can be used as a marker of malignant epithelial cells [88]. The LAMC2 has an epidermal growth factor (EGF)-like domain [89] which can be processed by MMP [90] to interrupt the hemidesmosomes via EGFR of b4 integrin during tumor cell migration. It has been shown that the MMP7, LAMC2, and EGFR expressions were correlated with tumor aggressiveness, advanced T grade, and tumor stage in GC tumors [39].

The human ADAMTS (a disintegrin and metalloproteinase with thrombospondin-like motifs) family of 19 secreted, multidomain proteolytic enzymes is involved in a wide range of biological processes including ECM assembly and degradation, hemostasis, organogenesis and the regulation of angiogenesis [91]. Immunohistochemical assessments have been shown the high expression levels of ADAMTS1, 8, and 18 in GC patients. There were correlations between increased ADAMTS1 and ADAMTS18 expressions and lymph node involvement which introduced them as the markers of lymphatic metastasis in GC patients. The ADAMTS8, ADAMTS18,

| Gene          | Results                                                                 | Country | population          | Year | Reference |
|---------------|------------------------------------------------------------------------|---------|---------------------|------|-----------|
| FN1           | Increased serum levels                                                  | Turkey  | 63 patients/30 controls | 2016 | Tas [58] |
| FNDC1         | Expression was correlated with sex, survival, and stage.               | China   | 90 patients         | 2018 | Ren [59]  |
| ANOS1         | Expression was correlated with stage and prognosis.                    | Japan   | 237 patients        | 2016 | Kanda [60]|
| ITGA4         | Methylation                                                            | Korea   | 46 patients         | 2004 | Park [61] |
| ICAM1 (CD54)  | Expressions were correlated with stage and lymph node involvement.     | China   | 84 patients         | 2014 | Dong [62] |
| CFL1          | Over expression                                                        | China   | 33 patients         | 2017 | Wang [63] |
| HMMR (CD168)  | Inverse correlation with lymph node involvement.                        | Japan   | 196 patients        | 2011 | Ishigami [64] |
| MFAP2         | Expression was correlated with depth of invasion, lymph node involvement, tumor stage, and poor overall survival | China   | 168 patients        | 2018 | Wang [65] |
| SPON2         | Expression was correlated with grade of tumor differentiation, depth of invasion, lymph node involvement, and advanced stages. | China   | 174 patients        | 2017 | Jin [66]  |

### Matricellular proteins and growth factors

| Gene          | Results                                                                 | Country | population          | Year | Reference |
|---------------|------------------------------------------------------------------------|---------|---------------------|------|-----------|
| SPARC         | Was correlated with serosal invasion and poor survival.                | Japan   | 227 patients        | 2013 | Sato [67] |
| SERPINE1 AND SPARC | Expressions were correlated with poor survival.                 | China   | 293 tumors/196 normal | 2018 | Liao [68] |
| SPARCL1       | Expression was correlated with prognosis, survival, size, and grade.  | China   | 1072 patients       | 2012 | Li [69]   |
| FGFR2 AND THBS1 | Over expressions                                                       | China   | 53 patients         | 2017 | Huang [70]|
| LTBP2         | Expression was correlated with depth of invasion, stage, lymph node involvement, poor survival. | China   | 174 patients        | 2018 | Wang [71] |
| POSTN         | Inverse correlation between expression and stage.                     | China   | 25 tumors/8 normal  | 2014 | LV [72]   |

### Proteoglycans and extra cellular glycoproteins

| Gene          | Results                                                                 | Country | population          | Year | Reference |
|---------------|------------------------------------------------------------------------|---------|---------------------|------|-----------|
| VCAN          | Expression was correlated with poor prognosis.                        | China   | 101 patients        | 2015 | Shen [73] |
| ASPN          | Over expression                                                        | China   | 46 patients         | 2015 | Ding [74] |
| LUM           | Up regulation in gastric CAFs was correlated with advanced stage, poor survival, depth of invasion, and lymph node involvement. | China   | 117 patients        | 2017 | Wang [75] |
| MUC2          | Was correlated with grade.                                             | Egypt   | 28 patients         | 2011 | Khattab [76] |
| Official symbol | Official full name                                      | Gene ID  | URL                                      |
|----------------|--------------------------------------------------------|----------|------------------------------------------|
| ADAMTS1        | ADAM metallopeptidase with thrombospondin type 1 motif 1 | 9510     | https://www.ncbi.nlm.nih.gov/gene/9510   |
| ADAMTS18       | ADAM metallopeptidase with thrombospondin type 1 motif 18 | 170,692  | https://www.ncbi.nlm.nih.gov/gene/170692  |
| ADAMTS8        | ADAM metallopeptidase with thrombospondin type 1 motif 8 | 11,095   | https://www.ncbi.nlm.nih.gov/gene/11095   |
| ANOS1          | Anosmin 1                                              | 3730     | https://www.ncbi.nlm.nih.gov/gene/3730    |
| ASPN           | Asporin                                                | 54,829   | https://www.ncbi.nlm.nih.gov/gene/54829   |
| BSG            | Basigin (Ok blood group) (EMMPRIN)                      | 682      | https://www.ncbi.nlm.nih.gov/gene/682     |
| CFL1           | Cofilin 1                                              | 1072     | https://www.ncbi.nlm.nih.gov/gene/1072    |
| CLDN4          | Claudin 4                                              | 1364     | https://www.ncbi.nlm.nih.gov/gene/1364    |
| CTHRC1         | Collagen triple helix repeat containing 1              | 115,908  | https://www.ncbi.nlm.nih.gov/gene/115908  |
| CXCR1          | C-X-C motif chemokine receptor 1                       | 3577     | https://www.ncbi.nlm.nih.gov/gene/3577    |
| CXCR2          | C-X-C motif chemokine receptor 2                       | 3579     | https://www.ncbi.nlm.nih.gov/gene/3579    |
| ECM1           | Extracellular matrix protein 1                         | 1893     | https://www.ncbi.nlm.nih.gov/gene/1893    |
| EGFR           | Epidermal growth factor receptor                       | 1956     | https://www.ncbi.nlm.nih.gov/gene/1956    |
| EMLIN1         | Elastin microfibril interacer 1                        | 11,117   | https://www.ncbi.nlm.nih.gov/gene/11117   |
| EMLIN2         | Elastin microfibril interacer 2                        | 84,034   | https://www.ncbi.nlm.nih.gov/gene/84034   |
| ETS1           | ETS proto-oncogene 1, transcription factor             | 2113     | https://www.ncbi.nlm.nih.gov/gene/2113    |
| FGF7           | Fibroblast growth factor 7                            | 2252     | https://www.ncbi.nlm.nih.gov/gene/2252    |
| FGF2           | Fibroblast growth factor receptor 2                    | 2263     | https://www.ncbi.nlm.nih.gov/gene/2263    |
| FN1            | Fibronectin 1                                          | 2335     | https://www.ncbi.nlm.nih.gov/gene/2335    |
| FNDC1          | Fibronectin type III domain containing 1               | 84,624   | https://www.ncbi.nlm.nih.gov/gene/84624   |
| FOXC2          | Forkhead box C2                                        | 2303     | https://www.ncbi.nlm.nih.gov/gene/2303    |
| HMRR           | Hyauronan mediated motility receptor (CD168)           | 3161     | https://www.ncbi.nlm.nih.gov/gene/3161    |
| HPSE           | Heparanase                                              | 10,855   | https://www.ncbi.nlm.nih.gov/gene/10855   |
| ICAM1          | Intercellular adhesion molecule 1 (CD54)               | 3383     | https://www.ncbi.nlm.nih.gov/gene/3383    |
| ITGA4          | Integrin subunit alpha 4                               | 3676     | https://www.ncbi.nlm.nih.gov/gene/3676    |
| LAMC2          | Laminin subunit gamma 2                                | 3918     | https://www.ncbi.nlm.nih.gov/gene/3918    |
| LGALS1         | Galectin 1                                             | 3956     | https://www.ncbi.nlm.nih.gov/gene/3956    |
| LGALS1         | Galectin 1                                             | 3956     | https://www.ncbi.nlm.nih.gov/gene/3956    |
| LLGL1          | LLGL scribble cell polarity complex component 1        | 3996     | https://www.ncbi.nlm.nih.gov/gene/3996    |
| LOX            | Lysyl oxidase                                          | 4015     | https://www.ncbi.nlm.nih.gov/gene/4015    |
| LOXL4          | Lysyl oxidase like 4                                   | 84,171   | https://www.ncbi.nlm.nih.gov/gene/84171   |
| LTB1P          | Latent transforming growth factor beta binding protein 2 | 4053   | https://www.ncbi.nlm.nih.gov/gene/4053   |
| LUM            | Lumican                                                | 4060     | https://www.ncbi.nlm.nih.gov/gene/4060    |
| MFAP2          | Microfibril associated protein 2                       | 4237     | https://www.ncbi.nlm.nih.gov/gene/4237    |
| MMP1           | Matrix metallopeptidase 1                              | 4312     | https://www.ncbi.nlm.nih.gov/gene/4312    |
| MMP14          | Matrix metallopeptidase 14                             | 4323     | https://www.ncbi.nlm.nih.gov/gene/4323    |
| MMP2           | Matrix metallopeptidase 2                              | 4313     | https://www.ncbi.nlm.nih.gov/gene/4313    |
| MMP24          | Matrix metallopeptidase 24                             | 10,893   | https://www.ncbi.nlm.nih.gov/gene/10893   |
| MMP25          | Matrix metallopeptidase 25                             | 64,386   | https://www.ncbi.nlm.nih.gov/gene/64386   |
| MMP7           | Matrix metallopeptidase 7                              | 4316     | https://www.ncbi.nlm.nih.gov/gene/4316    |
| MMP9           | Matrix metallopeptidase 9                              | 4318     | https://www.ncbi.nlm.nih.gov/gene/4318    |
| MMRN2          | Multimerin 2                                           | 79,812   | https://www.ncbi.nlm.nih.gov/gene/79812   |
| MUC2           | Mucin 2, oligomeric mucus/gel-forming                   | 4583     | https://www.ncbi.nlm.nih.gov/gene/4583    |
| MUC6           | Mucin 6, oligomeric mucus/gel-forming                   | 4588     | https://www.ncbi.nlm.nih.gov/gene/4588    |
| NODAL          | Nodal growth differentiation factor                     | 4838     | https://www.ncbi.nlm.nih.gov/gene/4838    |
and ADAMTS1 expressions were also associated with tumor stage [40].

Tissue inhibitors of metalloproteinases (TIMPs) as the main MMPs endogenous inhibitors bind to the enzyme catalytic site [92]. Regulation of basement membranes requires a balance between the functions of MMPs and TIMPs [93]. Up regulation of TIMP1 was reported in various tumors [94]. It has been observed that there was high levels of TIMP1 expression in GC tumors with advanced stages, increased depth of invasion, and metastatic lymph nodes. Moreover, the inflammatory infiltrate cells had higher levels of TIMP1 compared with tumor cells. Therefore, higher levels of expressions in advanced stages can be related to the synthetic role of inflammatory cells as well as tumor cells [41]. Another group has been observed that there were significant higher levels of MMP2, MMP24, and MMP25 expressions in GC compared with SG. Moreover, there were correlations between MMP14, TIMP3, and risk of GC progression [42].

Tissue factor pathway inhibitor 2 (TFPI2) is a serine proteinase inhibitor involved in protection of ECM from degradation [100]. Therefore, loss of TFPI2 increases the aggressive behavior of neoplastic cells [101]. The TFPI2 methylation levels were assessed in gastric tumors compared with corresponding normal margins, which showed TFPI2 hyper methylation in majority of GC tissues. Therefore, they suggested the TFPI2 hyper methylation as an efficient diagnostic marker of GC [46].

Regarding the levels of muscularis mucosa involvement, GC is classified into intramucosal and submucosal types, in which the submucosal tumors have higher rates of lymph node involvement. ETS1 is a transcription factor associated with mesodermal development during embryogenesis [102]. It is involved in tumor invasion through regulation of several genes such as urokinase type plasminogen activator, stromelysin-1, and collagenase-1 [103, 104]. It has been reported that the ETS1 over expression induced mucosal into the submucosal tumor invasion in GC patients. Whereas, there was not any ETS1 expression in normal gastric epithelium. The submucosal carcinomas had higher levels of ETS1 compared with mucosal adenocarcinomas which suggested the role of ETS1 in local invasion to submucosa during GC progression [47].

### Table 2  ECM related genes studied in GC patients (Continued)

| Official symbol | Official full name                  | Gene ID | URL                               |
|-----------------|-------------------------------------|---------|-----------------------------------|
| PCDH8           | Protocadherin 8                     | 5100    | [https://www.ncbi.nlm.nih.gov/gene/5100](https://www.ncbi.nlm.nih.gov/gene/5100) |
| PLOD2           | Procollagen-lysine,2-oxoglutarate 5-dioxynogenase 2 | 5352    | [https://www.ncbi.nlm.nih.gov/gene/5352](https://www.ncbi.nlm.nih.gov/gene/5352) |
| POSTN           | Periostin                           | 10,631  | [https://www.ncbi.nlm.nih.gov/gene/10631](https://www.ncbi.nlm.nih.gov/gene/10631) |
| SERPINE1        | Serpin family E member 1            | 5054    | [https://www.ncbi.nlm.nih.gov/gene/5054](https://www.ncbi.nlm.nih.gov/gene/5054) |
| SPARC           | Secreted protein acidic and cysteine rich | 6678    | [https://www.ncbi.nlm.nih.gov/gene/6678](https://www.ncbi.nlm.nih.gov/gene/6678) |
| SPARC1L1        | SPARC like 1                        | 8404    | [https://www.ncbi.nlm.nih.gov/gene/8404](https://www.ncbi.nlm.nih.gov/gene/8404) |
| SPON2           | Spondin 2                           | 10,417  | [https://www.ncbi.nlm.nih.gov/gene/10417](https://www.ncbi.nlm.nih.gov/gene/10417) |
| TFPI2           | Tissue factor pathway inhibitor 2   | 7980    | [https://www.ncbi.nlm.nih.gov/gene/7980](https://www.ncbi.nlm.nih.gov/gene/7980) |
| THBS1           | Thrombospondin 1                    | 7057    | [https://www.ncbi.nlm.nih.gov/gene/7057](https://www.ncbi.nlm.nih.gov/gene/7057) |
| TIMP1           | TIMP metallopeptidase inhibitor 1   | 7076    | [https://www.ncbi.nlm.nih.gov/gene/7076](https://www.ncbi.nlm.nih.gov/gene/7076) |
| TIMP3           | TIMP metallopeptidase inhibitor 3   | 7078    | [https://www.ncbi.nlm.nih.gov/gene/7078](https://www.ncbi.nlm.nih.gov/gene/7078) |
| VCAN            | Versican                            | 1462    | [https://www.ncbi.nlm.nih.gov/gene/1462](https://www.ncbi.nlm.nih.gov/gene/1462) |
Extracellular angiogenic factors

In this section, we summarize seven gene products including extracellular inducer (BSG: EMMPRIN), extracellular angiostatic protein (MMRN2), extracellular matrix glycoprotein (EMILIN2), heparinase (HPSE), collagen triple helix repeat containing 1 (CTHRC1), galectin 1 (LGALS1), and extracellular matrix protein 1 (ECM1).

Angiogenesis is a critical process during tumor growth which initiates from the outgrowth and migration of endothelial cells from parental vessels through vascular endothelial growth factor (VEGF). Cytokines, growth factors, and ECM proteins are important regulators of angiogenesis [105, 106]. In this process the MMPs has a key function in regulation of ECM in endothelial cells to form tube-like structures and blood vessels [107]. The extracellular MMP inducer (EMMPRIN) is a transmembrane immunoglobulin expressed on activated T cells, macrophages, endometrium, keratinocytes, and several solid tumors which induces MMP synthesis [108, 109]. It has been shown that there was a direct correlation between BSG expression, tumor size, and VEGF expression in GC patients. Moreover, the BSG over expressed tumors had higher ability for lymph node metastasis. They concluded that the BSG increases the tumor invasion and angiogenesis through MMP and VEGF up regulations in GC cells [48].

Multimerin 2 (MMRN2) is an extracellular angiostatic protein which suppresses the VEGFA/VEGFR2 signaling pathway [110]. It has been observed that there was high expression of MMRN2 in normal gastric mucosa along blood vessels, while the EMILIN 2 and EMILIN 1 expressions were limited to the lamina propria. The loss of EDEN family significantly affects the treatments efficiency and tumor progression [49]. Heparanase (HPSE) is an angiogenic factor and cleaves heparan sulfate (HS) side chains that are one of the main components of ECM and basement membrane. HS cleavage releases HS-linked angiogenic and growth factors such as FGF and VEGF [111]. Moreover, Heparan sulfate proteoglycans are suggested to induce stem cell properties through WNT and IL6/STAT5 pathways [112]. Therefore, HS and heparanase can be associated with various processes such as cell proliferation, adhesion, migration, and angiogenesis [113, 114]. It has been shown that the GA/AA genotypes of rs11099592 polymorphism were associated with superficial invasion of GC. Moreover, there was a significant correlation between rs6856901 polymorphism of HPSE and survival [50].

Collagen triple helix repeat containing 1 (CTHRC1) is a glycoprotein containing a short collagen triple helix repeat associated with cell migration through regulation of collagen matrix deposition [115]. It also functions in cell response to the arterial injury and vascular remodeling. It has been reported that there was a direct correlation between the levels of CTHRC1 expression and deeper depths of invasion which suggested that the CTHRC1 can be involved in GC progression and metastasis. Promoter hyper methylation has an important role in CTHRC1 silencing. In vitro study also showed that the levels of CTHRC1 expression was associated with TGFβ1 promoter demethylation [51]. Another study has been reported that the CTHRC1 up regulation was significantly associated with tumor stage, differentiation, survival, prognosis, depth of invasion, lymph node involvement, and tumor size among a sub population of GC patients [52]. During the metastasis process, tumor cells regulate growth factors, cytokines, ECM, and cancer-associated fibroblasts (CAFs) [116]. Galectin 1 (LGALS1) is a carbohydrate-binding lectin which is up regulated in CAFs and induces angiogenesis [117, 118]. Hh signaling pathway has a critical function during the EMT, angiogenesis, and tumor progression of GC through glioma-associated oncogene 1 (GLI1) [117–120]. The β1 integrin is a cell surface adhesion receptors which is inversely associated with cell adhesion loss and has a lactosamine sequence [121]. It has been shown that the CAFs induce epithelial to fibroblastoid phenotype, decrease E-cadherin, and increase vimentin in microenvironment through secretion of LGALS1 that functions via binding to the lactosamine sequence of β1 integrin [121–123]. Moreover, LGALS1 up regulated the GLI1 in GC cells introducing a key role of LGALS1 in GC metastasis through binding with β1 integrin [122].

Extracellular matrix protein 1 (ECM1) is involved in cell proliferation, migration, angiogenesis, and EMT [124]. During EMT process, cells change their epithelial properties to mesenchymal invasive phenotype via down regulation of E-cadherin and upregulation of vimentin [125]. ECM1 is also associated with glucose metabolism via LDHA, GLUT1, and HIF1A [126]. The ECM1 enhances the EMT and glucose metabolism through up regulation of ITGB4 and activation of FAK/Sox2 signaling pathway. Subsequent, SOX2 up regulation regulates HIF1A, vimentin, β-catenin, and E-cadherin expressions. It has been observed that there were correlations between high ECM1 levels, tumor relapse, poor survival, and advanced stages of tumor among GC patients [53]. Lymphangio genesis is a critical step during tumor progression that prepares more opportunities for tumor cells to spread using lymphatic system [127, 128]. ECM1 also has an important role in lymphangiogenesis [129]. It has been shown that the GC tumor tissues had significantly higher levels of ECM1 expressions compared with normal margins. There were also significant correlations between ECM1 expression, tumor depth of invasion, and stage [54]. CXCR1 and CXCR2 are IL-8 receptors associated with poor prognosis of GC [130]. CXCR1 is a G protein–coupled receptor involved in signal transduction [131], while CXCR2 is a G protein–coupled receptor associated with inflammation and angiogenesis [132].
has been shown that there were significant correlations between CXCR1, CXCR2, and MMP9 expressions in which CXCR1 and CXCR2 induce MMP9 expression through JNK/c-JUN and ERK/ETS1 signaling pathways [133–135].

**Cell adhesion and cytoskeletal organizers**

In this section, we summarize 13 gene products including a member of the protocadherin alpha gene cluster (PCDH8), laminin subunit gamma 2 (LAMC2), a claudin family member (CLDN4), cellular adhesion proteins (LLGL1 and ANOS1), fibronectin family members (FN1 and FNDC1), integrin alpha chain member (ITGA4), immunoglobulin family [ICAM1 (CD54)], cytoskeletal reorganizer (CFL1), hyaluronan mediated motility receptor (HMMR), microfibril associated protein (MFAP2), and an integrin ligand (SPON2).

Epithelial cell junctions have various functions such as communication, anchoring, and sealing. E-cadherin is the main protein of adherent junctions to stabilize the basolateral cell-cell contact. Therefore, E-cadherin loss increases cell migration [136]. Protocadherin (PCDH) is a member of the protocadherin alpha gene cluster functioning as tumor suppressors or oncogenes. They have an apoptotic role by inhibition of WNT pathway, or induce cell migration and drug resistance [137, 138]. It has been shown that the PCDH8 up regulation was significantly associated with poor prognosis and GC migration through up regulation of LAMC2 [55]. Claudins are the main components of tight junctions in epithelial and endothelial cell membranes which functions as primary barriers and regulate the polarity of epithelial cells [139, 140]. The claudin interacts with variety of proteins such as ZO proteins, RAB3B, PTEN, and ZONAB [141, 142]. It has been shown that there were associations between Claudin 4 (CLDN4) expression, depth of invasion, lymph node involvement, and MMP2,9 expressions which suggested the CLDN4 as a regulator of MMP2 and – 9 expressions [56].

LLGL1 is also a cellular adhesion protein that is involved in epithelial polarity and migration through a polarity complex comprising of PAR6, PAR3, PKC, and LLGL1 [143, 144]. It has been shown that there were significant correlations between LLGL1 loss, distant metastasis, and diffuse type of GC [57]. Fibronectin (FN) as a structural basement membrane glycoprotein has a critical function in cell adhesion, migration, and embryogenesis through cell surface receptors and integrins [145]. It is required for the proper collagen incorporation with ECM [146]. Fibronectin and collagen bind to integrins which are involved in cell–matrix adhesion and signal transduction [147, 148]. Fibronectin is also involved in cell proliferation and migration through mTOR signaling pathway [149, 150]. As a mesenchymal marker, it promotes TGFβ during EMT [151]. FN1 is also activator of STAT3 and MAPK signaling pathways to promote tumor progression and metastasis [152]. It has been observed that there was increased serum levels of fibronectin among GC patients which can be introduced as a diagnostic marker [58]. Fibronectin type III domain containing 1 (FNDC1) contains the type III domain of fibronectin [145]. It has been observed that there was significant higher levels of FNDC1 expression in GC compared with normal tissues. Moreover, there were significant correlations between FNDC1 expression, sex, survival, and tumor stage in GC patients [59].

The Anosmin 1 (ANOS1) is a cell adhesion protein associated with migration of gonadotropin-releasing hormone neurons. It increases the malignant behavior through integrin signaling pathways in brain tumors and promotes cell migration and drug resistance in colon cancer [153, 154]. It has been reported that there were increased levels of ANOS1 expressions in GC cell lines in comparison with normal epithelial cell line which suggested ANOS1 as an oncogene in GC. The GC tissues also showed ANOS1 over expression which was correlated with tumor stage, prognosis, and diffuse type. PCR array also showed ITGAV, FOXC2, and NODAL expressions parallel with ANOS1, while TFP12 down regulation [60]. ITGAV is a member of the ECM and involved in EMT [155]. The FOXC2 is an important transcription factor during EMT [156]. NODAL is belonged to the TGF-β family which has key role in cell growth and migration [157]. Integrins are cell-surface receptors involving in cell–cell and cell–ECM interactions and tumor metastasis [158, 159]. It has been reported that the ITGAV4 expression is lost in the majority of GC cell lines and tumor tissues through DNA methylation [61].

Leptin is an adipokine that is involved in body weight homeostasis through regulation of energy metabolism [160]. Leptin also has a key role in cell migration via up regulation of CD54 in allergic inflammation [161]. ICAM1 (CD54) is belonged to the immunoglobulin family which binds with ITGB2 and ITGAM to facilitate the metastasis and hiding toward immunocytes [162]. It functions as an intercellular adhesion protein and has inhibitory role on tight junction formation in blood-testis barrier during spermatogenesis [163]. Various factors such as RHO and ROCK regulate the ICAM1 expression [164]. It has been shown that the leptin induces GC migration through up regulation of ICAM1 and activation of RHO/ROCK signaling pathway. Moreover, there were correlations between ICAM1 levels, stage, and lymph node involvement in GC patients [62].

Cofilin 1 (CFL1) is a cytoskeletal reorganizer and EMT regulator in tumor cells [165]. It has been shown that there were consistent CFL1 up regulation in GC tissues. TGFBI induced CFL1 expression in the gastric tumor cells. The lack of CFL1 inhibited actin depolymerization and microfilaments function. G-actin can be irreversibly aggregated into F-actin which blocks the cell surface pseudopodia formation. TGFBI up regulated the CFL1,
G-actin, and F-actin expressions which resulted in microfilament polymerization. Therefore, it was concluded that CFL1 promotes the EMT process and gastric tumor cell invasion through cytoskeletal rearrangement [63]. Hyaluronic acid (HA) as an ECM component is mainly secreted by fibroblasts in response to humoral signals of tumor cells [166]. HMMR is an intracellular HA binding protein belonging to the microtubule-associated protein (MAP) family which is associated with microfilament formation and cell movement in tumor cells. An expression study has been performed on the levels of HMMR protein expressions in GC patients and showed positive expression in cellular mucosa and cytoplas in tumor cells, while it was expressed rarely in normal gastric mucosa. There was also a significant converse correlation between HMMR expression and lymph node involvement [64].

Microfibril associated protein 2 (MFAP2) is one of the main regulators of microfibril function which binds with ECM and TGF-β through specific domains in carboxyl and amino-terminal, respectively [167, 168]. It has been reported that there was MFAP2 up regulation in GC tissues which was associated with depth of invasion, lymph node involvement, tumor stage, and poor survival. Moreover, MFAP2 induces the EMT process and gastric tumor cell proliferation through TGF-β/SMAD2/3 signaling pathway. The MFAP2 knockdown significantly modulated the EMT factors in which Vimentin and Snail expressions were decreased while E-cadherin was up regulated [65]. Spondin 2 (SPON2) is a secreted ECM protein belonged to the F-spondin family which is an integrin ligand [169]. It has been observed that there was SPON2 increased expression in GC tissues in comparison with the normal margins. There were significant correlations between SPON2 up regulation, grade of tumor differentiation, depth of invasion, lymph node involvement, and advanced stages in GC cases. The cases with SPON2 over expression had lower survival compared with under expressed GC patients. The tumors with advanced depth of invasion and metastatic lymph nodes had increased levels of SPON2 expression. Moreover, they showed that there was a direct association between SPON2 and MMP9 expressions among GC patients [66].

### Matricellular proteins and growth factors

In this section, we summarize seven matricellular protein gene products including secreted protein acidic and cysteine rich (SPARC), SPARC like protein 1 (SPARCL1), serpin family E member 1 (SERPINE1), fibroblast growth factor receptor 2 (FGFR2), thrombospondin 1 (THBS1), latent transforming growth factor beta binding protein 2 (LTBP2), and periostin (POSTN).

Matricellular proteins are ECM glycoproteins that includes osteopontin, tenascins, POSTN, SPARC, and thrombospondins that are associated with embryogenesis, stem cell niches, and tissue remodeling [79, 170]. Most of them regulate cell–matrix adhesions via binding with fibronectin or collagen. SPARC is a matricellular protein produced by endothelial cells which regulates cell–matrix interactions during tissue remodeling through binding with ECM components such as collagen and fibronectin [171, 172]. It has been shown that there was increased expression of SPARC in GC tissues in comparison with normal margins. There were correlations between SPARC up regulation, serosal invasion, poor survival [67]. SERPINE1 and SPARC over expressions were also observed in GC tissues which were correlated with poor survival [68]. SPARC like protein 1 (SPARCL1) is a matricellular protein involving in tumor progression and tissue regeneration [173]. It has been reported that there was decreased expression of SPARCL1 in GC tissues compared with normal margins. There were significant correlations between SPARCL1 down regulation, poor prognosis, survival, histological type, and tumor size. There was also an association between SPARCL1 expression and grade of tumor differentiation in which there was a significant declining levels of expression toward the poorly differentiated tumors [69]. The thrombospondin is a calcium binding glycoprotein involving in wound healing and angiogenesis in which it inhibits angiogenesis via interaction with CD36 on endothelial cells and promoting apoptosis [174]. Fibroblast growth factors (FGFs) are heparin-binding growth factors involving in cell proliferation and angiogenesis through FGF receptors (FGFRs). FGF7 as a keratinocyte growth factor promotes FGFR2 dimerization and initiates various signaling pathways such as MAPK and PI3K/Akt [175, 176]. Thrombospondin 1 (THBS1) is an endogenous angiogenesis inhibitor [177] which is associated with FGF7/FGFR2 during GC migration and invasion. It has been shown that there were higher levels of FGFR2 and THBS1 expressions in GC tumors compared with normal margins. There was an association between THBS1 expression and well/moderate differentiation which suggests a less aggressive behavior. Since there was a direct correlation between THBS1 and FGFR2 expressions, the FGF7/FGFR2 may induce GC invasion through THBS1. Moreover, it was shown that the FGF7/FGFR2 up regulates THBS1 through PI3K/Akt/mTOR pathway [70].

LTBP2 is belonged to the ECM proteins which has calcium-binding epidermal growth factor like and TGF-β binding domains [178]. LTBP2s have an important role in ECM regulation and TGF-β activation [179]. It has been reported that there were increased expression of LTBP2 in GC tissues and cell lines which was correlated...
with depth of invasion, lymph node involvement, poor survival, and tumor stage [71]. POSTN is one of the ECM components that has oncogetic role through integrins and EGFR to activate the AKT/PKB and FAK signaling pathways in different tumors [180, 181]. It has been shown that there were lower levels of periglandular POSTN expression in GC tissues compared with normal margins. The metastatic lymph nodes had significantly lower levels of POSTN expression. Moreover, there was an inverse correlation between POSTN expression and tumor stage. It seems that this tumor suppressor role of POSTN can be related to the probable correlation between POSTN, P53, and E-cadherin through Rb/E2F1/p14ARF/MDM2 signaling pathway [72].

Proteoglycans and extra cellular glycoproteins
In this section, we summarize four matricellular protein gene products including versican (VCAN), asporin (ASPN), lumican (LUM), and mucin 2 (MUC2).

The ECM is composed of various proteins such as proteoglycans (PGs) and collagens that organize physiological and pathological functions [182]. Proteoglycans are glycosylated proteins spreading throughout the mammalian tissues which are associated with tissue remodeling, cellular adhesion, and signaling pathways. VCAN as a chondroitin sulfate PG is mainly accumulated in tumor stroma and has key functions in regulation of cell proliferation, self-renewal, and migration [183, 184]. It has been shown that the GC tissues had significantly higher levels of VCAN expression. Moreover, there was a correlation between VCAN over expression and GC poor prognosis [73].

Asporin (ASPN) is one of the members of small Leucine-rich proteoglycan (SLRP) family that is associated with ECM modification [185]. It has been reported that there was significantly increased levels of ASPN expression in GC tissues compared with normal margins. The migration of gastric tumor cells also significantly decreased following the ASPN knockdown. Moreover, it seems that there were some correlations between CD44, MMP2, and ASPN expression in which ASPN silencing significantly decreased the levels of CD44 and MMP2 expressions in GC tissues. Therefore in can be concluded that the ASPN is involved in regulation of GC migration and metastasis via EGFR-CD44/MMP2 signaling pathway [74]. Cancer-associated fibroblasts (CAF) are stromal cells characterized by their spindle-shape morphology, fibroblast activation protein alpha, and α-smooth muscle actin expressions [186]. These cells are associated with tumor progression via secretion of several factors such as cytokines and growth factors [187]. LUM is an external proteoglycan belonged to the SLRPs family. It seems that the LUM exerts its role in gastric tumor progression through integrin β1-FAK signaling pathway. FAK as a tyrosine kinase is activated by integrin or growth factor receptors and has key role in regulation of cyclins and signaling pathways such as PI3K/AKT and MAPK [188, 189]. It has been observed that there was LUM up regulation in gastric CAFs which was directly correlated with advanced stage, poor survival, depth of invasion, and lymph node involvement. LUM knockdown in CAFs also suppresses the GC cell proliferation, migration, and in vivo tumorigenesis [75].

Mucins are glycoproteins comprising of a mucin core and O-linked oligosaccharides produced by epithelial tissues which are involved in epithelial surfaces protection, inflammation, renewal, and tumorigenesis [190]. Although, expressions of MUC1, MUC5AC, and MUC6 are observed in normal gastric mucosa [191], there is not any MUC2 expression in normal gastric mucosa [192]. It has been observed that majority of GC tissues had MUC2 expression. Moreover, MUC2 reactivity was directly correlated with grade of differentiation [76]. Sialic acids are monosaccharides that are attached to the membranous glycoproteins and glycolipids. It has been shown that there was a correlation between tumor invasion and deregulation of terminal 2, 3-linked sialic acids [193, 194]. The up regulation of 2, 3-linked sialic acid residues were associated with lymph node involvement and depth of tumor invasion. MAL as a specific sialic acid-binding lectin was observed in gastric cancerous regions, whereas it was not detected in normal margins [195].

Conclusion
Regarding the importance of extra cellular matrices and components in GC metastasis and invasion, in present review we summarized 48 of significant ECM related factors which have been reported among GC patients. It has been shown that the intra cellular signaling pathways associated with tumor invasion also exert their role through regulation of local ECM. Therefore, according to the lower complexity of ECM compared with intracellular signaling pathways, the ECM can be a more reliable tumor therapeutic target with lower side effects. Indeed this review paves the way of introducing an extra cellular based prognostic and diagnostic panel marker for the GC patients.

Abbreviations
ANOS1: Anosmin 1; ASPN: Asporin; CAFs: Cancer-associated fibroblasts; CFL1: Cofilin 1; COX2: Cyclooxygenase 2; CTSCR1: Collagen triple helix repeat containing 1; ECM: Extracellular matrix; EMT: Epithelial-mesenchymal transition; FGFRs: Fibroblast growth factors; FGFs: FGF receptors; FN: Fibronectin; FNDC1: Fibronectin type III domain containing 1; GC: Gastric cancer; GLI1: GLI family zinc finger 1; HA: Hyaluronic acid; HMMR: Hyaluronan mediated motility receptor; HPSE: Heparanase; LAMC2: Laminin subunit gamma 2; LGALS1: Galectin 1; LUM: Lumican; MAP: Microtubule associated protein; MFAP2: Microfibril associated protein 2; MMPs: Matrix metalloproteinases; MMRN2: Multimerin 2; PCDH: Protocadherins; PGs: Proteoglycans; POSTN: Peristin; SLRP: Small Leucine-rich proteoglycan; SPON2: Spondin 2; SPARC: SPARC like protein 1; TFP2: Tissue factor pathway inhibitor 2;
References

1. Bissell MJ, Labarge MA. Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? Cancer cell. 2005;7(1):17–23.
2. Hynes RO. The extracellular matrix not just pretty fibrils. Science. 2009;326(5957):1216–9.
3. Cox TR, Erler JT. Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. Dis Model Mech. 2011;4(2):165–78.
4. Moghbeli M, Moaven O, Memar B, Raziei HR, Aarabi A, Dadkhah E, et al. Role of mYML1 and E-Cadherin promoter methylation in gastric cancer progression. J Gastrointest Cancer. 2014;45(1):40–7.
5. Ozbek S, Balasubramanian PG, Chiquet-Ehrismann R, Tucker RP, Adams JC. The evolution of extracellular matrix. Mol Biol Cell. 2010;21(24):4300–5.
6. Aitken KJ, Bagli DJ. The bladder extracellular matrix. Part I: architecture, development and disease. Nat Rev Urol. 2013;10(9):596–711.
7. Thompson LD, Tlsty TD. Patenting stem cell research: a conflict of interest? Nat Rev Cancer. 2007;7(7):508–14.
8. Page-McCaw A, Ewald AJ, Wern Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol. 2007;8(3):221–33.
9. Engelb M, Rasch MG, Weaver VM. Dynamic interplay between the collagen scaffold and tumor evolution. Curr Opin Cell Biol. 2010;22(5):597–705.
10. Wyckoff JB, Wang Y, Lin EY, Li JF, Goswami S, Stanley ER, et al. The effect of environmental chemicals on the tumor microenvironment. J Natl Cancer Inst. 2013;105(21):1566–83.
11. Neri G, Delhumeau D, Guzman-Lopez J, Pardo A, Capella C, et al. The effect of environmental chemicals on the tumor microenvironment. J Biol Chem. 2015;290(10):6079–93.
12. Costantini F, Aitman TJ. The role of genetic variation in mouse and human disease. Nat Rev Genet. 2009;10(10):683–96.
13. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.
14. Moghbeli M, Mosonnien Mozaffari H, Memar B, Forghaniard MD, Ghoolamine M, Abbaszadegan MR. Role of MAML1 in targeted therapy against the esophageal cancer stem cells. J Transl Med. 2019;17(1):126.
15. Ozbek S, Balasubramanian PG, Chiquet-Ehrismann R, Tucker RP, Adams JC. The evolution of extracellular matrix. Mol Biol Cell. 2010;21(24):4300–5.
16. Keely PJ. Mechanisms by which the extracellular matrix and integrin signaling act to regulate the switch between tumor suppression and tumor promotion. J Mammary Gland Biol Neoplasia. 2011;16(3):205–19.
17. Schwartz MA, Assoian RK. Integrins and cell proliferation: regulation of cyclin-dependent kinases via cytoplasmic signaling pathways. J Cell Sci. 2001;114(Pt 14):2533–60.
18. Dangerfield J, Larbi KY, Huang MT, Dexpert A, Nourshargh S. PECAM-1 (CD31) homophilic interaction up-regulates alphabeta1 on transmigrated neutrophils in vivo and plays a functional role in the ability of alphab eta integrins to mediate leukocyte migration through the perivascular basement membrane. J Exp Med. 2002;196(9):1201–11.
19. Birimbaus L, State of the science of endocrine disruptors. Environ Health Perspect. 2013;121(4):A107.
20. Le Broux MA, Starenkovc I. Tumor-host interactions: the role of inflammation. Histochem Cell Biol. 2008;130(6):1079–90.
21. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tsitoy TD, Cunha GR. Carcinogenesis associated with the microenvironment: inflammatory mediators. J Surg Res. 1999;69(1):5002–11.
22. Weaver VM, Gilbert P. Watch thy neighbor: cancer is a communal affair. J Cell Sci. 2004;117(Pt 8):1287–90.
23. Duffield JS, Loper M, Thannickal VI, Wynn TA. Host responses in tissue repair and fibrosis. Annu Rev Pathol. 2013;8:241–76.
24. Atkinson MJ. Radiation treatment effects on the proteome of the tumour microenvironment. Adv Exp Med Biol. 2013;900(94):49–60.
25. Jensen K, Nizzamundov D, Guerrier M, Afroz S, Dostal D, Glaser S. General mechanisms of nicotine-induced fibrogenesis. FASEB J. 2012;26(12):4778–87.
26. Casey SC, Vaccari M, Al-Mull A, Al-Termaia R, Amedei A, Barcellona-Hoff MH, et al. The effect of environmental chemicals on the tumor microenvironment. Carcinogenesis. 2015;36(Suppl 11):615–80.
27. Verhaegh GJ, Ong AM, van der Heyden MA, van der Marck SS, de Boer AA, van der Burg SH, et al. The role of matrix metalloproteinases in the pathogenesis of breast cancer. Breast Cancer Res Treatment. 2005;91(2):165–75.
28. Feinberg AP, Vogelstein B. A gain of function mutation in the hTERT gene causes immortalization of human diploid fibroblasts. Proc Natl Acad Sci. 1983;80(9):5043–7.
29. Martella L, Bertozzi S, Londero AP, Steffan A, De Paoli P, Bertola G. Surgery for liver metastases from gastric cancer: a meta-analysis of observational studies. Medicine. 2015;94(31):e1113.
30. Riihimaki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. Metastatic spread in patients with gastric cancer: Oncotarget. 2016;7(32):52307–16.
31. Leeming DJ, Bay-Jensen AC, Vassiliadis E, Larsen MR, Henriksen K, Karsdal MA. Post-translational modifications of the extracellular matrix are key events in cancer progression: opportunities for biochemical marker development. Biomarkers. 2011;16(3):193–205.
32. Matsunuma S, Due N, Nakayama H, Kitada Y, Yoshida K, Yamaguchi Y, et al. A single nucleotide polymorphism in the MMP-9 promoter affects tumor progression and invasive phenotype of gastric cancer. J Cancer Res Clin Oncol. 2005;131(1):19–25.
33. Moczkow B, Lutkewicz-Zajac M, Guzinska-Ustymowicz K, Gryko M, Czyzewska J, Kemenova A, et al. Expression of matrix metalloproteinase-9 in the neoplastic and interstitial inflammatory infiltrate cells in gastric cancer. Folia Histochim Cytobios. 2009;47(3):491–6.
34. Dragutinovic V, Izrael-Zickovic L, Radovanovic. Relation of matrix metalloproteinase-9 to different stages of tumors in the serum of gastric cancer. Dig Dis Sci. 2009;54(1):1203–7.
35. Matsunuma S, Due N, Kitada Y, Chayama K, Yoshida K, Yamaguchi Y, et al. A single nucleotide polymorphism in the MMP-1 promoter is correlated with histological differentiation of gastric cancer. J Cancer Res Clin Oncol. 2005;131(1):19–25.
36. Dedong H, Bin Z, Peisheng S, Hongwei X, Qinghui Y. The contribution of the genetic variations of the matrix metalloproteinase-1 gene to the genetic susceptibility of gastric cancer. Genet Test Mol Biomarkers. 2014;18(10):675–82.
37. Mena J, Wietken JP, Nordling S, Kojak A, Ristamaki A, Haglund C. MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer. J Clin Pathol. 2006;59(6):S18–23.
(LI-1 beta) in human fibroblasts and BC-8701 breast cancer cells. J Cell Biochem. 1997;66(3):322–36.
85. Tryggvason K, Hoyhtya M, Pycke C. Type IV collagenases in invasive tumors. Breast Cancer Res Treat. 1993;24(3):209–18.
86. Callejas NA, Casado M, Diaz-Guerra MJ, Bosca L, Martin-Sanz P. Expression of cycloxygenase-2 promotes the release of matrix metalloproteinase-2 and -9 in fetal rat hepatocytes. Hepatology. 2001;33(4):860–6.
87. Colognato H, Yurchenco PD. Form and function: the laminin family of heterotrimers. Dev Dyn. 2000;218(2):231–34.
88. Koshikawa N, Moriyama K, Takamura H, Mizushima H, Nagashima Y, Yanoma S, et al. Overexpression of laminin gamma2 chain monomer in invading gastric carcinoma cells. Cancer Res. 1999;59(21):5596–601.
89. Schenk S, Hintermann E, Bilbain M, Koshikawa N, Hojjila C, Khokha R, et al. Binding to EGF receptor of a laminin-5 EGF-like fragment liberated during MMP-dependent mammary gland involution. J Cell Biol. 2003;161(1):197–209.
90. Veitch DP, Nokelainen P, McGowan KA, Nguyen TT, Nguyen NE, Stephenson R, et al. Mammalian tolloid metalloproteinase and not matrix metalloprotease 2 or membrane type 1 metalloprotease processes laminin-5 in keratinocytes and skin. J Biol Chem. 2003;278(15):15661–8.
91. Wagstaff L, Kelwick R, Decock I, Edwards DR. The roles of ADAMTS metalloproteinases in tumorigenesis and metastasis. Front Biosci. 2011;16:1861–72.
92. Nottall RK, Sampieri CL, Pennington CJ, Gill SE, Schultz GA, Edwards DR. Expression analysis of the entire MMP and TIMP gene families during mouse tissue development. FEBS lett. 2004;563(1–3):129–34.
93. Crawford HC, Matrinan LM. Tumor and structural expression of matrix metalloproteinases and their role in tumor progression. Invasion metastasis. 1994;1(4):1355–60.
94. de Mingo M, Moran A, Sanchez-Pernaute A, Iniesta P, Diez-Valladares L, de Mingo M, et al. Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK) co-expression in metastatic serous ovarian carcinoma. Clin Exp Metastasis. 2003;20(7):621–31.
95. Gabison EE, Hoang-Xuan T, Mauvrit A, Menashi S. EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair. Biochimie. 2005;87(4–6):361–8.
96. Lorezon E, Colladell R, Andreuzzi E, Marastoni S, Todaro F, Schiappacciass M, et al. MULTIMERIN2 impairs tumor angiogenesis and growth by interfering with VEGF-A/VEGFR2 pathway. Oncogene. 2012;31(26):3316–47.
97. Vreys V, David G. Mammalian heparanase: what is the message? J Cell Mol Med. 2007;11(3):427–52.
98. Ibrahim SA, Hassan H, Villano L, Kumar SK, Kumar AV, Kelsch R, et al. Syndecan-1 (CD138) modulates triple-negative breast cancer stem cell properties via regulation of LRP-6 and IL-6-mediated STAT3 signaling. PloS one. 2013;8(12):e85737.
99. Ian N, Elin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol. 2006;38(12):2018–39.
100. Sanderson RD, Yang Y, Suva LJ, Kelly T. Heparan sulfate proteoglycans and heparanase—partners in osteolytic tumor growth and metastasis. Matrix Bio. 2004;23(6):341–52.
101. Pyagay P, Herculot M, Wang Q, Lehnert W, Belden J, Liaw L, et al. Collagen triple helix repeat containing 1, a novel secreted protein in injured and diseased arteries, inhibits collagen expression and promotes cell migration. Circ Res. 2005;96(2):261–8.
102. Xiong Y, Wang LF, Wang RF. Role of cancer-associated fibroblasts in invasion and dissemination of cancer cells. World J Gastroenterol. 2015;21(33):9717–26.
103. Chen J, Tang D, Wang S, Li QG, Zhang JR, Li P, et al. High expressions of galectin-1 and VEGF are associated with poor prognosis in gastric cancer patients. Tumour Biol. 2014;35(3):2513–9.
104. Tang D, Gao J, Wang S, Ye N, Chong Y, Huang Y, et al. Cancer-associated fibroblasts promote angiogenesis in gastric cancer through galectin-1 expression. Tumour Biol. 2016;37(2):1889–99.
105. Gao Q, Yuan Y, Gan HZ, Peng Q. Resveratrol inhibits the hedgehog signaling pathway and epithelial-mesenchymal transition and suppresses gastric cancer invasion and metastasis. Oncol Lett. 2015;9(5):2381–7.
106. Katoh Y, Kato M. Integrative genomic analyses on GLI1: positive regulation of GLI1 by hedgehog-GLI TGFBeta-Smads, and RTK-PI3K-AKT signals, and negative regulation of GLI1 by notch-CLS-HE4, and GPCR-G-PKA signals. Int J Oncol. 2009;35(3):187–92.
107. Sakaguchi M, Imazumy Y, Shingo T, Tada H, Hayama K, Yamada O, et al. Regulation of adult neural progenitor cells by Galectin-1/beta1 integrin interaction. J Neurochem. 2010;113(6):1516–24.
108. Chong Y, Tang D, Xiong Q, Jiang X, Xu C, Huang Y, et al. Galectin-1 from cancer-associated fibroblasts promotes angiogenesis in gastric cancer through galectin-1 overexpression. World J Cancer Res. 2016;37(2):1889–99.
109. Moiseeva EP, Williams B, Goodall AH, Samani NJ. Galectin-1 interacts with beta-1 subunit of integrin. Biochem Biophys Res Commun. 2003;310(3):1010–6.
110. Chen H, Jia W, Li J. ECM1 promotes migration and invasion of hepatocellular carcinoma by inducing epithelial-mesenchymal transition. World J Surg Oncol. 2016;14(1):195.
111. Yan Y, Wang LF, Wang RF. Role of cancer-associated fibroblasts in invasion and dissemination of cancer cells. World J Gastroenterol. 2015;21(33):9717–26.
112. Lee KM, Nam K, Oh S, Lim J, Lee T, Shin I. ECM1 promotes the Warburg effect through EGF-mediated activation of PKM2. Cellular Signal. 2015;27(2):228–35.
113. Achen MG, Stacker SA. Molecular control of lymphatic metastasis. Ann N Y Acad Sci. 2008;1133:225–34.
114. Zhuang Z, Jian P, Yang H, Hou Z, Wang Y, Wang Y, et al. Identification of oral cancer cell-induced changes in gene expression profile of lymphatic endothelial cell. Cancer Invest. 2008;26(10):1002–7.
115. Wu QN, She HQ, Liang J, Huang YF, Yang QM, Yang QL, et al. Expression and clinical significance of extracellular matrix protein 1 and vascular endothelial growth factor-C in lymphatic metastasis of human breast cancer. BMC Cancer. 2012;12:474.
116. Wang JP, Hu WM, Wang KS, Yu J, Luo BH, Wu C, et al. Expression of C-X-C chemokine receptor types 1/2 in patients with gastric
181. Baril P, Gangeswaran R, Mahon PC, Caulee K, Kocher HM, Harada T, et al. Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3K pathway. Oncogene. 2007;26(14):2082–94.

182. Zigrino P, Loffek S, Mauch C. Tumor-stroma interactions: their role in the control of tumor cell invasion. Biochimie. 2005;87(3–4):221–8.

183. Ricciardelli C, Sakko AJ, Ween MP, Russell DL, Honsfall DJ. The biological role and regulation of versican levels in cancer. Cancer Metastasis Rev. 2009;28(1–2):233–45.

184. Du WW, Fang L, Yang X, Sheng W, Yang BL, Seth A, et al. The role of versican in modulating breast cancer cell self-renewal. Mol Cancer Res. 2013;11(5):443–55.

185. Lorenzo P, Aspberg A, Onnerfjord P, Bayliss MT, Neame PJ, Heinegard D. Identification and characterization of asporin. A novel member of the leucine-rich repeat protein family closely related to decorin and biglycan. J Biol Chem. 2001;276(15):12201–11.

186. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6(5):392–401.

187. Jedenskó R, Victor BC, Pogoróslí I, Sióane BF. Fibroblast hepatocyte growth factor promotes invasion of human mammary ductal carcinoma in situ. Cancer Res. 2009;69(23):9148–55.

188. Bouchard V, Demers MJ, Thibodeau S, Laquerre V, Fujita N, Tsuruo T, et al. Fak/Src signaling in human intestinal epithelial cell survival and anoikis: differentiation state-specific uncoupling with the PI3-K/Akt-1 and MEK/Erk pathways. J Cell Physiol. 2007;212(3):717–28.

189. Bouchard V, Harnois C, Demers MJ, Thibodeau S, Laquerre V, Gauthier R, et al. B1 integrin/Fak/Src signaling in intestinal epithelial crypt cell survival: integration of complex regulatory mechanisms. Apoptosis. 2008;13(4):531–42.

190. Gendler SJ, Spicer AP. Epithelial mucin genes. Annu Rev Physiol. 1995;57:607–34.

191. Lee HS, Lee HK, Kim HS, Yang HK, Kim YI, Kim WH. MUC1, MUC2, MUC5AC, and MUC6 expressions in gastric carcinomas: their roles as prognostic indicators. Cancer. 2001;92(6):1427–34.

192. Pinto-de-Sousa J, David L, Reis CA, Gomes R, Silva L, Pimenta A. Mucins MUC1, MUC2, MUC5AC and MUC6 expression in the evaluation of differentiation and clinical behavior of gastric carcinoma. Virchows Arch. 2002;440(3):304–10.

193. Chen S, Fukuda M. Cell type-specific roles of carbohydrates in tumor metastasis. Methods Enzymol. 2006;416:371–80.

194. Miyagi T, Wada T, Yamaguchi K, Hata K. Sialidase and malignancy: a minireview. Glycoconj J. 2004;20(3):189–98.

195. Wang FL, Cui SX, Sun LP, Qu XJ, Xie YY, Zhou L, et al. High expression of alpha 2, 3-linked sialic acid residues is associated with the metastatic potential of human gastric cancer. Cancer Detect Prev. 2009;32(5–6):437–43.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.